Rifampicin-resistant tuberculosis prevention and control in Jiangsu Province from 2013 to 2023
10.3760/cma.j.cn112338-20240802-00472
- VernacularTitle:2013-2023年江苏省利福平耐药结核病防治效果分析
- Author:
Hui DING
1
;
Quanji YU
1
;
Xiaoyan DING
1
;
Yan SHAO
1
;
Peng LU
1
;
Zhongqi LI
1
;
Limei ZHU
1
;
Qiao LIU
1
Author Information
1. 江苏省疾病预防控制中心慢性传染病防制所，南京 210009
- Publication Type:Journal Article
- Keywords:
Tuberculosis;
Drug-resistance;
Rifampicin;
Joinpoint regression;
Prevention and treatment effectiveness
- From:
Chinese Journal of Epidemiology
2025;46(4):655-661
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the trends in detection, treatment, and outcomes of rifampicin-resistant tuberculosis (TB) in Jiangsu Province from 2013 to 2023, assess the effectiveness of control policies and measures for drug-resistant TB, and provide evidence for better control of drug-resistant TB.Methods:Data and indicators related to the screening, diagnosis, treatment, and outcomes of rifampicin-resistant TB in Jiangsu Province from 2013 to 2023 were obtained from the Tuberculosis Management Information System. The Joinpoint regression method was employed to analyze the trends over this period, and annual percent change (APC) and average annual percent change (AAPC) were calculated. A comparative analysis was also conducted to evaluate the changes before and after implementing relevant policies and measures.Results:From 2013 to 2023, the number of registered rifampicin-resistant TB patients in Jiangsu Province showed a consistent upward trend (APC=AAPC=1.45%, P=0.035). The screening rates for drug resistance among new TB patients in high-risk groups and the proportion of molecular biological testing for drug resistance all exhibited increasing trends, with a notable turning point occurring in 2018. The trend of the treatment enrollment rate for rifampicin-resistant TB patients experienced a significant shift in 2020, showing a marked increase from 2013 to 2020 (APC=12.91%, P=0.008). The treatment success rate of rifampicin-resistant TB patients also showed a significant upward trend after a turning point in 2020 (APC=9.94%, P=0.004). Conclusion:From 2013 to 2023, significant progress was seen in preventing and treating rifampicin-resistant TB in Jiangsu Province, with relevant policies and measures proving to be highly effective.
